{
    "ticker": "VRAX",
    "name": "Verrica Pharmaceuticals Inc.",
    "description": "Verrica Pharmaceuticals Inc. is a clinical-stage dermatology company focused on developing and commercializing innovative therapies for common skin conditions. Founded in 2018 and headquartered in West Chester, Pennsylvania, Verrica aims to improve the quality of life for patients suffering from dermatological disorders. The company's lead product candidate, VP-102, is a proprietary formulation of cantharidin designed to treat external warts, including common and plantar warts. This non-invasive treatment is currently undergoing clinical trials and has shown promising results in effectively eliminating warts while minimizing discomfort for patients. Verrica is committed to advancing dermatological care through rigorous research and development, collaborating with leading experts in dermatology to bring safe and effective treatments to market. With a strong pipeline of product candidates targeting various dermatological conditions, Verrica is positioned to become a leader in the dermatology space. The company is dedicated to patient education and access, ensuring that individuals have the necessary information and resources to manage their skin health effectively.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "West Chester, Pennsylvania, USA",
    "founded": "2018",
    "website": "https://www.verricapharma.com",
    "ceo": "David P. Pritchard",
    "social_media": {
        "twitter": "https://twitter.com/VerricaPharma",
        "linkedin": "https://www.linkedin.com/company/verrica-pharmaceuticals/"
    },
    "investor_relations": "https://investors.verricapharma.com",
    "key_executives": [
        {
            "name": "David P. Pritchard",
            "position": "CEO"
        },
        {
            "name": "Thomas H. Barlow",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Product Candidates",
            "products": [
                "VP-102"
            ]
        }
    ],
    "seo": {
        "meta_title": "Verrica Pharmaceuticals Inc. | Innovative Dermatology Solutions",
        "meta_description": "Explore Verrica Pharmaceuticals Inc., a clinical-stage company dedicated to developing innovative therapies for skin conditions. Learn about our lead product candidate and commitment to dermatological care.",
        "keywords": [
            "Verrica Pharmaceuticals",
            "VP-102",
            "Dermatology",
            "Skin Treatments",
            "Cantharidin"
        ]
    },
    "faq": [
        {
            "question": "What is Verrica Pharmaceuticals known for?",
            "answer": "Verrica Pharmaceuticals is known for developing innovative therapies for dermatological conditions, particularly external warts."
        },
        {
            "question": "Who is the CEO of Verrica Pharmaceuticals?",
            "answer": "David P. Pritchard is the CEO of Verrica Pharmaceuticals Inc."
        },
        {
            "question": "Where is Verrica Pharmaceuticals headquartered?",
            "answer": "Verrica Pharmaceuticals is headquartered in West Chester, Pennsylvania, USA."
        },
        {
            "question": "What is VP-102?",
            "answer": "VP-102 is a proprietary formulation of cantharidin being developed to treat external warts."
        },
        {
            "question": "When was Verrica Pharmaceuticals founded?",
            "answer": "Verrica Pharmaceuticals was founded in 2018."
        }
    ],
    "competitors": [
        "AMRN",
        "SNDX",
        "PBYI"
    ],
    "related_stocks": [
        "VRTX",
        "INCY",
        "REGN",
        "GILD"
    ]
}